Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - Other
Ratios

Caribou Biosciences (CRBU) Leases (2022 - 2025)

Caribou Biosciences (CRBU) has disclosed Leases for 4 consecutive years, with $16.0 million as the latest value for Q3 2025.

  • On a quarterly basis, Leases fell 21.91% to $16.0 million in Q3 2025 year-over-year; TTM through Sep 2025 was $16.0 million, a 21.91% decrease, with the full-year FY2024 number at $20.0 million, down 9.8% from a year prior.
  • Leases was $16.0 million for Q3 2025 at Caribou Biosciences, down from $16.5 million in the prior quarter.
  • In the past five years, Leases ranged from a high of $25.7 million in Q1 2022 to a low of $16.0 million in Q3 2025.
  • A 4-year average of $21.8 million and a median of $22.2 million in 2023 define the central range for Leases.
  • Peak YoY movement for Leases: dropped 7.9% in 2023, then fell 22.11% in 2025.
  • Caribou Biosciences' Leases stood at $24.2 million in 2022, then dropped by 8.45% to $22.2 million in 2023, then fell by 9.8% to $20.0 million in 2024, then fell by 20.02% to $16.0 million in 2025.
  • Per Business Quant, the three most recent readings for CRBU's Leases are $16.0 million (Q3 2025), $16.5 million (Q2 2025), and $19.5 million (Q1 2025).